Compare VanEck Australian Floating Rate ETF (FLOT) vs TG Therapeutics Inc (TGTX) Price & Performance

FLOT trades at $50.96 with minimal daily movement (+0.1%) amid bearish technical signals. The ETF faces concentration risk with 47% bank exposure while benefiting from floating rate exposure during Fed tightening cycles. Recent dividend payments of $0.17-0.18 reflect current yield environment, though technical indicators show strong selling pressure with moving averages and ADX signaling bearish momentum.

The floating rate structure positions FLOT to benefit from continued Fed hawkishness, but high bank concentration presents sector-specific risks. Current technical weakness suggests near-term pressure, while the fund's yield advantage over cash equivalents remains attractive for income-focused investors in rising rate environments.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.